Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
August 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
June 18, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
June 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
June 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
May 30, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
May 22, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 08, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
March 19, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
March 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
February 28, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
February 28, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
December 18, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
November 20, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.